

# EXMceuticals

09:25 03 Feb 2020

## EXMceuticals appoints former head of Portugal's health regulator to advisory board

EXMceuticals Inc (CSE:EXM) has appointed the former president of Portugal's health regulator, Dr Eurico Castro Alves, to its advisory board.

The new advisor is also the founder of WiseHS medical and Pharmaceutical consulting, a European business and clinical consultancy that offers guidance to the medical cannabis industry.

Vancouver-based EXMceuticals engaged WiseHS to help the firm get its cannabis R&D license for its Portuguese laboratory, CEO Jonathan Summers told shareholders.

### READ: EXMceuticals adds leading UK cannabis lawyer Nick Davis to advisory team

"(Dr Castro Alves) engagement will clearly assist the future development of EXMceuticals in Portugal," Summers said. "He and EXM share a common goal to establish Portugal as a centre for medical cannabis healthcare and science."

A medical doctor by background, Castro Alves completed general surgery training in the US and obtained the degree of instructor in advanced trauma life support in Illinois. In Europe, he led Portuguese health regulator Infarmed's board of directors and assisted numerous medical non-profits.

EXMceuticals appointed Castro Alves in observance of the regime governing the exercise of functions by political officers and senior public officeholders in Portugal, according to the firm.

Summers said that the next step in the company's strategy is to have a licensed and operating high-quality ingredients factory that will produce to medical standards and have many industrial applications.

EXMceuticals also said that chief strategy officer Marc Bernier was stepping down from the role to move to a consultancy relationship. Bernier was appointed to the company's board of directors and granted options to purchase 1.5 million shares at C\$2 for a ten-year period from the date of grant.

Contact Angela at [angela@proactiveinvestors.com](mailto:angela@proactiveinvestors.com)

Follow her on Twitter @AHarmantas

**Price:** 0.2

**Market Cap:** \$7.9 m

### 1 Year Share Price Graph



September 2019 March 2020 September 2020

### Share Information

**Code:** EXM

**Listing:** CSE

<b>52 week</b>	<b>High</b>	<b>Low</b>
	1.55	0.05

**Sector:** Cannabis

**Website:** [exmceuticals.com](http://exmceuticals.com)

### Company Synopsis:

*EXMceuticals is a medical cannabis company that strongly believes in the potential health and wellness benefits of hemp and cannabis. EXMceuticals is an emerging player in the market, with high ambitions and potential in becoming a large scale producer of high-grade EU GMP cannabis and hemp ingredients.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of EXMceuticals named herein, including the promotion by the Company of EXMceuticals in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).